International Journal of Clinical Oncology

, Volume 19, Issue 3, pp 490–496 | Cite as

Prognosis analysis of sarcomatous intrahepatic cholangiocarcinoma from a review of the literature

  • Go Watanabe
  • Hiroshi Uchinami
  • Masato Yoshioka
  • Hiroshi Nanjo
  • Yuzo Yamamoto
Original Article



Sarcomatous intrahepatic cholangiocarcinoma (ICC) is a rare histological variant of ICC. The prognosis of sarcomatous ICC is poorly understood.


We analyzed the prognosis of sarcomatous ICC by reviewing the previous reports and our own case.


Only 15 cases of sarcomatous ICC have been reported in the English-language literature so far. Median survival time of patients with sarcomatous ICC with and without surgery was 11 and 3 months, respectively. Survival rate of patients operated on for sarcomatous ICC was similar to that of patients with ordinary ICC without surgery in the early postoperative period. In the long-term view, however, the prognosis for the patients with sarcomatous ICC receiving surgery was better than that for the patients with ordinary ICC without surgery.


Although the prognosis for the patients with sarcomatous ICC was poor even after curative resection, surgery would be justified as the primary treatment for sarcomatous ICC.


Intrahepatic cholangiocarcinoma Sarcomatous Prognosis 


Conflict of interest

The authors have no potential conflict of interest.

Supplementary material

10147_2013_586_MOESM1_ESM.doc (54 kb)
Supplementary material 1 (DOC 54 kb)
10147_2013_586_MOESM2_ESM.doc (59 kb)
Supplementary material 2 (DOC 59 kb)


  1. 1.
    Kwon JH, Kang YN, Kang KJ (2007) Carcinosarcoma of the liver: a case report. Korean J Radiol 8:343–347PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Sasaki M, Nakanuma Y, Nagai Y et al (1991) Intrahepatic cholangiocarcinoma with sarcomatous transformation: an autopsy case. J Clin Gastroenterol 13:220–225PubMedCrossRefGoogle Scholar
  3. 3.
    Haratake J, Yamada H, Horie A et al (1992) Giant cell tumor-like cholangiocarcinoma associated with systemic cholelithiasis. Cancer 69:2444–2448PubMedCrossRefGoogle Scholar
  4. 4.
    Nakajima T, Tajima Y, Sugano I et al (1993) Intrahepatic cholangiocarcinoma with sarcomatous change. Clinicopathologic and immunohistochemical evaluation of seven cases. Cancer 72:1872–1877PubMedCrossRefGoogle Scholar
  5. 5.
    Honda M, Enjoji M, Sakai H et al (1996) Case report: intrahepatic cholangiocarcinoma with rhabdoid transformation. J Gastroenterol Hepatol 11:771–774PubMedCrossRefGoogle Scholar
  6. 6.
    Itamoto T, Asahara T, Katayama K et al (1999) Double cancer—hepatocellular carcinoma and intrahepatic cholangiocarcinoma with a spindle-cell variant. J Hepatobiliary Pancreat Surg 6:422–426PubMedCrossRefGoogle Scholar
  7. 7.
    Shimada M, Takenaka K, Rikimaru T et al (2000) Characteristics of sarcomatous cholangiocarcinoma of the liver. Hepatogastroenterology 47:956–961PubMedGoogle Scholar
  8. 8.
    Kaibori M, Kawaguchi Y, Yokoigawa N et al (2003) Intrahepatic sarcomatoid cholangiocarcinoma. J Gastroenterol 38:1097–1101PubMedCrossRefGoogle Scholar
  9. 9.
    Sato K, Murai H, Ueda Y et al (2006) Intrahepatic sarcomatoid cholangiocarcinoma of round cell variant: a case report and immunohistochemical studies. Virchows Arch 449:585–590PubMedCrossRefGoogle Scholar
  10. 10.
    Tsou YK, Wu RC, Hung CF et al (2008) Intrahepatic sarcomatoid cholangiocarcinoma: clinical analysis of seven cases during a 15-year period. Chang Gung Med J 31:599–605PubMedGoogle Scholar
  11. 11.
    Malhotra S, Wood J, Mansy T et al (2010) Intrahepatic sarcomatoid cholangiocarcinoma. J Oncol 2010:1–4CrossRefGoogle Scholar
  12. 12.
    Inoue Y, Lefor AT, Yasuda Y (2012) Intrahepatic cholangiocarcinoma with sarcomatous changes. Case Rep Gastroenterol 6:1–4PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRefGoogle Scholar
  14. 14.
    Dingle BH, Rumble RB, Brouwers MC (2005) The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 19:711–716PubMedGoogle Scholar
  15. 15.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277PubMedCrossRefGoogle Scholar
  16. 16.
    Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204PubMedCrossRefGoogle Scholar
  17. 17.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2013

Authors and Affiliations

  • Go Watanabe
    • 1
  • Hiroshi Uchinami
    • 1
  • Masato Yoshioka
    • 1
  • Hiroshi Nanjo
    • 2
  • Yuzo Yamamoto
    • 1
  1. 1.Department of Gastroenterological SurgeryAkita University Graduate School of MedicineAkitaJapan
  2. 2.Division of Clinical PathologyAkita University Graduate School of MedicineAkitaJapan

Personalised recommendations